Wire · operational-macro
Nasdaq listing awaits Singapore's US$1.5 billion AI drug-discovery biotech Nanyang Biologics
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 October 2026 · Fusion42 review
Singapore-based biotech startup Nanyang Biologics is preparing for a Nasdaq listing via a SPAC merger valued between US$1.5 billion and US$2.2 billion, driven by their proprietary AI drug-discovery platform and potential first-in-class cancer treatment.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You should watch Nasdaq and SPAC listings in AI-driven biotech as a clear channel for capital to fuel global expansion. Nanyang Biologics’ move signals growing investor acceptance of AI-first drug development that could open new routes for funding and partnerships.
◆ Coverage
1 source · 14 Oct 2026
◆ Related on Wire
◆ Topics